Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: histamine signaling and hair follicle research
Also known as: Cetirizine dihydrochloride
Cetirizine dihydrochloride is the salt used in common 10 mg oral tablets and 1 mg/mL oral solutions. Its approved oral antihistamine evidence is separate from experimental topical 1% studies in pattern hair loss. Small topical trials have reported mixed signals, and a systematic review judged the evidence limited and at moderate-to-high risk of bias. Research powder should not be represented as an approved topical formulation.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: DailyMed labeling, primary topical studies, systematic review, and current laboratory catalogs
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
1 mL of 1% solution daily
Context: male pattern-hair case-controlled study PMID 33417284
Formulation: Concentration, vehicle, treated area, and product sterility are formulation-specific.
Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.
1 mL of 1% solution daily
Context: 2025 nine-completer pilot PMID 41625414
Formulation: Concentration, vehicle, treated area, and product sterility are formulation-specific.
Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.
No route-specific amount established in the reviewed record.
Context: The catalog identifies this route, but its reviewed sources do not establish a separate amount and schedule for it.
Formulation: Oral-mucosal formulations are not dose-equivalent to injectable or topical formulations.
Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.
10 mg
Context: FDA labeling for IV cetirizine in adults and children 12 years and older with acute urticaria.
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.
The row now distinguishes 1 g and 5 g laboratory powder from approved 10 mg tablets and 1 mg/mL oral solutions. Topical hair research is off-label and does not justify self-compounding from bulk powder.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.